Home    Back

93. Primary biliary cholangitis
230 clinical trials,   215 drugs   (DrugBank: 51 drugs),   34 drug target genes,   107 drug target pathways

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00844402
(ClinicalTrials.gov)		January 200613/2/2009Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisSafety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisPrimary Biliary Cirrhosis;HypercholesterolemiaDrug: AtorvastatinMedical University of GrazNULLCompleted18 Years70 YearsBoth40Phase 3Austria
2EUCTR2005-002160-28-AT
(EUCTR)		23/09/200519/08/2005Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosisSafety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC.Trade Name: Sortis
Product Name: Sortis 10 mg
INN or Proposed INN: Atorvastatin		Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and HepatologyNULLNot RecruitingFemale: yes
Male: yes		80Austria